Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Feb;8(1):3-6.
doi: 10.1177/23971983221129211. Epub 2022 Oct 11.

Very Early Diagnosis of Systemic Sclerosis: Deciphering the heterogeneity of systemic sclerosis in the very early stages of the disease

Alain Lescoat  1   2
Affiliations
Editorial

Very Early Diagnosis of Systemic Sclerosis: Deciphering the heterogeneity of systemic sclerosis in the very early stages of the disease

Alain Lescoat. J Scleroderma Relat Disord. 2023 Feb.

Abstract

The early diagnosis of systemic sclerosis has been a major challenge for the scleroderma community in the past 50 years. The recent publication of the predictive value of the VEDOSS (Very Early Diagnosis of Systemic Sclerosis) criteria in the Lancet Rheumatology in December 2021 has provided an unprecedented insight in the early stages of the disease. This editorial discusses the main findings from this 2021 VEDOSS publication and highlights key unanswered questions to be proposed on the research agenda in very early systemic sclerosis.

Keywords: Systemic sclerosis; anti-centromere antibodies; anti-nuclear antibodies; anti-topoisomerase antibodies; diagnosis; preventive medicine.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lescoat A, Cavalin C, Ehrlich R, et al.. The nosology of systemic sclerosis: how lessons from the past offer new challenges in reframing an idiopathic rheumatological disorder. Lancet Rheumatol 2019; 1: e257–264. - PubMed
    1. Bellando-Randone S, Galdo FD, Lepri G, et al.. Progression of patients with Raynaud’s phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). Lancet Rheumatol 2021; 3: e834–843. - PubMed
    1. van den Hoogen F, Khanna D, Fransen J, et al.. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against rheumatism collaborative initiative: ACR/EULAR classification criteria for SSc. Arthritis Rheumat 2013; 65: 2737–2747. - PMC - PubMed
    1. Avouac J, Fransen J, Walker UA, et al.. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 2011; 70(3): 476–481. - PubMed
    1. Domsic RT, Gao S, Laffoon M, et al.. Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design. Rheumatology 2021; 60: 4662–4670. - PMC - PubMed

Publication types